Post-transplant lymphoproliferative disorders.
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after hematopoietic stem cell or solid organ transplantation. The majority of PTLD is of B-cell origin and associated with Epstein-Barr virus (EBV). During the past decade progress has been made in better understanding the pathogenesis of PTLD, and early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have assisted in the identification of high-risk patients. In addition, novel immunotherapies have been developed, including the use of monoclonal antibodies and adoptive transfer of EBV-specific T cells. Despite these advances, it remains a major challenge to define indications for preemptive therapies for PTLD and to integrate novel therapeutic approaches with conventional therapies.
Gottschalk
Stephen
S
Center for Cell and Gene Therapy, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA. smg@bcm.tmc.edu
Rooney
Cliona M
CM
Heslop
Helen E
HE
D004305:Dose-Response Relationship, Drug; D018380:Hematopoietic Stem Cell Transplantation; D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D015448:Leukemia, B-Cell / Q000209:etiology / Q000628:therapy; D016393:Lymphoma, B-Cell / Q000209:etiology / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D011183:Postoperative Complications / Q000209:etiology*; D011379:Prognosis; D012307:Risk Factors; D016378:Tissue Transplantation; D014774:Virulence
D007166:Immunosuppressive Agents